Alligator and Aptevo Announce Positive Data of Dose Escalation Ph of ALG.APV-527
Frontline treatment with the combination of the CD40-directed monoclonal antibody agonist mitazalimab and modified FOLFIRINOX (mFOLFIRINOX) continued to produce responses in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to updated data from the phase 2 OPTIMIZE-1 trial (NCT04888312).1
Alligator Bioscience (Alligator) has announced an expansion to its licence agreement and research collaboration with Orion Corporation (Orion). The link-up is focused on the discovery and development of new bispecific antibody cancer therapeutics.
LUND, Sweden I January 2, 2023 I Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces strong interim results from the ongoing OPTIMIZE-1 Phase 2 trial of the company’s lead asset mitazalimab in 1st line metastatic pancreatic cancer.
Lund, Sweden, November 8, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that Shanghai Henlius Biotech, Inc. has received investigational new drug (IND) approval from China's National Medical Products Administration (NMPA) for a Phase 2 clinical trial of AC101 (HLX22), a monoclonal HER2 antibody, in combination with anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab), HANQUYOU (trastuzumab) and chemotherapy as a 1st line treatment for HER2-positive locally advanced/metastatic gastric cancer patients.
The research involves patients with advanced solid malignancies on tumour-directed therapy. Alligator Bioscience has announced positive safety data from the 900mg dose cohort in its phase 1, first-in-human clinical trial with its drug candidate, ATOR-1017. The treatment is being developed as a tumour-directed therapy for advanced and metastatic cancer.
Lund, Sweden, September 14, 2022 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces a poster presentation on the OPTIMIZE-1 Phase 1b/2 trial of mitazalimab in combination with modified FOLFIRINOX in first-line metastatic pancreatic cancer with the company's lead asset mitazalimab (CD40 mAb) at the 2022 AACR (American Association for Cancer Research) Special Conference on Pancreatic Cancer, being held in Boston September 13-16.